Skip to main content
Log in

Identification of free and conjugated metabolites of mesocarb in human urine by LC-MS/MS

  • Original Paper
  • Published:
Analytical and Bioanalytical Chemistry Aims and scope Submit manuscript

Abstract

The objective of the present study was to investigate mesocarb metabolism in humans. Samples obtained after administration of mesocarb to healthy volunteers were studied. The samples were extracted at alkaline pH using ethyl acetate and salting-out effect to recover metabolites excreted free and conjugated with sulfate. A complementary procedure was applied to recover conjugates with glucuronic acid or with sulfate consisting of the extraction of the urines with XAD-2 columns previously conditioned with methanol and deionized water; the columns were then washed with water and finally eluted with methanol. In both cases, the dried extracts were reconstituted and analyzed by ultra-performance liquid chromatography–tandem mass spectrometry. Chromatographic separation was carried out using a C18 column (100 mm × 2.1 mm i.d., 1.7 µm particle size) and a mobile phase consisting of water and acetonitrile with 0.01% formic acid with gradient elution. The chromatographic system was coupled to a mass spectrometer with an electrospray ionization source working in positive mode. Metabolic experiments were performed in multiple-reaction monitoring mode by monitoring one transition for each potential mesocarb metabolite. Mesocarb and 19 metabolites were identified in human urine, including mono-, di-, and trihydroxylated metabolites excreted free as well as conjugated with sulfate or glucuronic acid. All metabolites were detected up to 48 h after administration. The structures of most metabolites were proposed based on data from reference standards available and molecular mass and product ion mass spectra of the peaks detected. The direct detection of mesocarb metabolites conjugated with sulfate and glucuronic acid without previous hydrolysis has been described for the first time. Finally, a screening method to detect the administration of mesocarb in routine antidoping control analyses was proposed and validated based on the detection of the main mesocarb metabolites in human urine (p-hydroxymesocarb and p-hydroxymesocarb sulfate). After analysis of several blank urines, the method demonstrated to be specific. Extraction recoveries of 100.3 ± 0.8 and 105.9 ± 10.8 (n = 4), and limits of detection of 0.5 and 0.1 ng mL−1 were obtained for p-hydroxymesocarb sulfate and p-hydroxymesocarb, respectively. The intra- and inter-assay precisions were estimated at two concentration levels, 50 and 250 ng mL−1, and relative standard deviations were lower than 15% in all cases (n = 4).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. World Anti-Doping Agency (WADA). The World Anti Doping Code. The 2009 Prohibited List International Standard. (2008) http://www.wada-ama.org/rcontent/document/2009_Prohibited_List_ENG_Final_20_Sept_08.pdf

  2. Polgár M, Vereczeley L, Szporny L, Czira G, Tamás J, Gács-Baitz E, Holly S (1979) Xenobiotica 9:511–520

    Article  Google Scholar 

  3. Ventura R, Nadal T, Alcalde P, Segura J (1993) J Chromatogr 647:203–210

    Article  CAS  Google Scholar 

  4. Ventura R, Nadal T, Alcalde P, Pascual JA, Segura J (1993) J Chromatogr A 655:233–242

    Article  CAS  Google Scholar 

  5. Thieme D, Grobe J, Lang R, Mueller RK (1994) In: Donike M, Greyer H, Gotzmann A, Mareck-Engelke U (eds) Proceedings of the 12th Cologne Workshop on Dope Analysis. Cologne, Germany, pp275–285

  6. Appolonova SA, Shpak AV, Semenov VA (2004) J Chromatogr B 800:281–289

    Article  CAS  Google Scholar 

  7. Shpak AV, Appolonova SA, Semenov VA (2005) J Chromatogr Sci 43:11–21

    CAS  Google Scholar 

  8. Vahermo M, Suominen T, Leinonen A, Yli-Kauhaluoma J (2009) Arch Pharm Chem Life Sci 342:201–209

    Article  CAS  Google Scholar 

  9. Pyo H, Park SJ, Park J, Yoo JK, Yoon B (1996) J Chromatogr B 687:261–269

    Article  CAS  Google Scholar 

  10. Deventer K, Van Eenoo P, Delbeke PT (2005) Rapid Commun Mass Spectrom 19:90–98

    Article  CAS  Google Scholar 

  11. Kang MJ, Hwang YH, Lee W, Kim DH (2007) Rapid Commun Mass Spectrom 21:252–264

    Article  CAS  Google Scholar 

  12. Mazzarino M, Botrè F (2006) Rapid Commun Mass Spectrom 26:3465–3476

    Article  Google Scholar 

  13. Ventura R, Roig M, Monfort N, Sáez P, Bergés R, Segura J (2008) Eur J Mass Spectrom 14:191–200

    Article  CAS  Google Scholar 

  14. Kolmonen M, Leinonen A, Pelander A, Ojanperä I (2007) Anal Chim Acta 585:94–102

    Article  CAS  Google Scholar 

  15. Kolmonen M, Leinonen A, Kuuranne T, Pelander A, Ojanperä I (2009) Drug Test Anal 1:250–266

    Article  CAS  Google Scholar 

  16. Lee J, Jeung H, Kim K, Lho D (1999) J Mass Spectrom 34:1079–1086

    Article  CAS  Google Scholar 

  17. Jiménez C, de la Torre R, Segura J, Ventura R (2006) Rapid Commun Mass Spectrom 20:858–864

    Article  Google Scholar 

  18. Jiménez C, Ventura R, Segura J (2002) J Chromatogr B Analyt Technol Biomed Life Sci 767:341–351

    Article  Google Scholar 

  19. World Anti-Doping Agency (WADA). Minimum required performance limits for detection of prohibited substances. WADA Technical Document TD2009MRPL (2009) http://www.wada-ama.org/rtecontent/document/MINIMUM_REQUIRED_PERFORMANCE_LEVELS_TD_v1_0_January_2009.pdf

Download references

Acknowledgments

The financial support received from Consell Català de l’Esport, Generalitat de Catalunya (Spain) and Ministerio de Educación y Ciencia (Spain; project number DEP2007-73224-C03-03) to R. V. and the World Anti-Doping Agency WADA (Grant 05D4JY/2005) and Research Foundation of Clinical Chemistry (Kliinisen kemian tutkimussäätiö, Helsinki, Finland) to J. Y.-K. is greatly acknowledged. The collaboration of Dr. Magí Farré to obtain administration study samples is gratefully acknowledged.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R. Ventura.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Fig. S1

Screening method: MRM chromatograms of blank urine (top) and chromatograms of a quality control sample spiked with 50 ng mL-1 of p-hydroxymesocarb (2) and p-hydroxymesocarb sulfate (11) (bottom) (PDF 575 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gómez, C., Segura, J., Monfort, N. et al. Identification of free and conjugated metabolites of mesocarb in human urine by LC-MS/MS. Anal Bioanal Chem 397, 2903–2916 (2010). https://doi.org/10.1007/s00216-010-3756-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00216-010-3756-y

Keywords

Navigation